

# Carl A Olsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11699788/publications.pdf>

Version: 2024-02-01

148  
papers

7,846  
citations

50276

46  
h-index

53230

85  
g-index

161  
all docs

161  
docs citations

161  
times ranked

3545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 195-195.	1.6	0
2	Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e15-78.e21.	1.6	3
3	Effects of age on outcomes in men receiving treatment for metastatic castration-resistant prostate cancer (mCRPC): Analysis of Medicare fee for service (FFS) claims data.. Journal of Clinical Oncology, 2020, 38, e17590-e17590.	1.6	0
4	Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846â€“52. European Urology, 2019, 76, e98.	1.9	0
5	Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 177-177.	1.6	1
6	Re: Management of the Urologic Sepsis Syndrome. European Urology, 2018, 73, 977-978.	1.9	0
7	Racial or Ethnic and Socioeconomic Disparities in Prostate Cancer Survivors' Prostate-specific Quality of Life. Urology, 2018, 112, 132-137.	1.0	24
8	Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. Journal of Clinical Oncology, 2018, 36, 234-234.	1.6	0
9	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. Journal of Clinical Oncology, 2018, 36, 5041-5041.	1.6	0
10	A new technique of reporting prostate biopsy to predict prostatectomy outcome.. Journal of Clinical Oncology, 2017, 35, e544-e544.	1.6	0
11	A new prostate cancer biopsy reporting system with prognostic potential.. Journal of Clinical Oncology, 2017, 35, e16572-e16572.	1.6	0
12	Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.. Journal of Clinical Oncology, 2016, 34, 193-193.	1.6	1
13	Trends in histology of newly diagnosed prostate cancer subsequent to USPSTF PSA screening recommendation.. Journal of Clinical Oncology, 2016, 34, 68-68.	1.6	1
14	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, e16503-e16503.	1.6	0
15	Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 5025-5025.	1.6	1
16	Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.. Journal of Clinical Oncology, 2015, 33, e16027-e16027.	1.6	1
17	Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.. Journal of Clinical Oncology, 2015, 33, 272-272.	1.6	2
18	Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. PLoS ONE, 2015, 10, e0143404.	2.5	41

#	ARTICLE	IF	CITATIONS
19	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2014, 32, 5051-5051.	1.6	2
20	Urinary function after image-guided intensity modulated radiation therapy (IG-IMRT) of localized prostate cancer.. Journal of Clinical Oncology, 2014, 32, 141-141.	1.6	0
21	Infectious complications after prostate needle biopsy: Predictors of bacteremia and sepsis.. Journal of Clinical Oncology, 2014, 32, e16035-e16035.	1.6	0
22	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. Journal of Clinical Oncology, 2014, 32, 5040-5040.	1.6	0
23	Editorial comment. Arab Journal of Urology Arab Association of Urology, 2013, 11, 360-361.	1.5	0
24	Outcomes of Distal Ureteral Reconstruction Through Reimplantation With Psoas Hitch, Boari Flap, or Ureteroneocystostomy for Benign or Malignant Ureteral Obstruction or Injury. Urology, 2013, 82, 231-236.	1.0	68
25	Utilization and cancer detection by U.S. prostate biopsies (2005-2011).. Journal of Clinical Oncology, 2013, 31, 107-107.	1.6	0
26	Utilization and cancer detection by U.S. prostate biopsies (2005-2011).. Journal of Clinical Oncology, 2013, 31, e16076-e16076.	1.6	1
27	Does size matter? The significance of prostate size on pathologic and functional outcomes in patients undergoing robotic prostatectomy. Arab Journal of Urology Arab Association of Urology, 2011, 9, 159-164.	1.5	5
28	Changes in Prognostic Significance and Predictive Accuracy of Gleason Grading System Throughout PSA Era: Impact of Grade Migration in Prostate Cancer. Urology, 2007, 70, 706-710.	1.0	17
29	Preoperative Serum Prostate Specific Antigen Remains a Significant Prognostic Variable in Predicting Biochemical Failure After Radical Prostatectomy. Journal of Urology, 2006, 175, 1663-1667.	0.4	12
30	Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology, 2006, 67, 260-264.	1.0	107
31	Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology, 2006, 67, 942-945.	1.0	33
32	Reevaluation of TNM staging of renal cortical tumors: Recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology, 2006, 68, 287-291.	1.0	31
33	Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU International, 2005, 95, 27-30.	2.5	54
34	988: Re-Evaluation of the TNM Staging of Conventional Renal Cortical Tumors: Outcome of T1N0M0 and T3AN0M0 Renal Cortical Tumors are Equivalent. Journal of Urology, 2005, 173, 267-267.	0.4	1
35	The evolving role of partial nephrectomy in the management of renal cell carcinoma. Current Oncology Reports, 2003, 5, 239-244.	4.0	27
36	RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology, 2003, 61, 967-971.	1.0	20

#	ARTICLE	IF	CITATIONS
37	The relationship of long term global temperature change and human fertility. <i>Medical Hypotheses</i> , 2003, 61, 21-28.	1.5	14
38	SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2001, 166, 882-886.	0.4	78
39	Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation. <i>Prostate</i> , 2001, 49, 9-18.	2.3	6
40	SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2001, , 882-886.	0.4	1
41	Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells. <i>Prostate</i> , 2000, 43, 175-183.	2.3	19
42	Microvessel Density as a Predictor of PSA Recurrence After Radical Prostatectomy. <i>American Journal of Clinical Pathology</i> , 2000, 113, 555-562.	0.7	94
43	Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients. <i>Urology</i> , 2000, 56, 393-398.	1.0	19
44	THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2000, 163, 1413-1418.	0.4	28
45	CIRCULATING PROSTATE DERIVED CELLS IN PATIENTS WITH PROSTATE ADENOCARCINOMA. <i>Journal of Urology</i> , 2000, 163, 1631-1631.	0.4	2
46	DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 163, 834-837.	0.4	62
47	Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 958-958.	1.6	308
48	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. , 1999, 86, 492-497.		64
49	Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. , 1999, 84, 360-364.		46
50	A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. , 1999, 82, 846-852.		41
51	Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. <i>Urology</i> , 1999, 53, 440-445.	1.0	116
52	Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. <i>Urology</i> , 1999, 54, 1039-1043.	1.0	86
53	CASTRATION INDUCES ACUTE VASOCONSTRICTION OF BLOOD VESSELS IN THE RAT PROSTATE CONCOMITANT WITH A REDUCTION OF PROSTATIC NITRIC OXIDE SYNTHASE ACTIVITY. <i>Journal of Urology</i> , 1999, 162, 1527-1531.	0.4	47
54	Continent urinary diversion. <i>Urologic Clinics of North America</i> , 1999, 26, 125-147.	1.8	40

#	ARTICLE	IF	CITATIONS
55	CAN PERINEURAL INVASION ON PROSTATE NEEDLE BIOPSY PREDICT PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY?. <i>Journal of Urology</i> , 1999, 162, 103-106.	0.4	68
56	A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. <i>International Journal of Cancer</i> , 1999, 82, 846-852.	5.1	2
57	CASTRATION INDUCES ACUTE VASOCONSTRICTION OF BLOOD VESSELS IN THE RAT PROSTATE CONCOMITANT WITH A REDUCTION OF PROSTATIC NITRIC OXIDE SYNTHASE ACTIVITY. <i>Journal of Urology</i> , 1999, , 1527-1531.	0.4	1
58	Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. , 1998, 36, 201-206.		154
59	URINARY CONTINENCE AFTER RADICAL PROSTATECTOMY: THE COLUMBIA EXPERIENCE. <i>Journal of Urology</i> , 1998, 159, 1276-1280.	0.4	79
60	REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ASSAYS FOR PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1997, 24, 367-378.	1.8	36
61	Molecular Staging of Prostate Cancer. III. Effects of Cystoscopy and Needle Biopsy on the Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Urology</i> , 1997, 157, 1748-1751.	0.4	13
62	Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. <i>Urology</i> , 1997, 49, 973-980.	1.0	58
63	PRETREATMENT PROSTATE SPECIFIC ANTIGEN DOUBLING TIMES: USE IN PATIENTS BEFORE RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1997, 158, 1876-1879.	0.4	49
64	The Relationship of Sperm Counts to Birth Rates: A Population Based Study. <i>Journal of Urology</i> , 1997, 157, 840-843.	0.4	15
65	Abnormal prostate development in C3(1)-bcl-2 transgenic mice. , 1997, 32, 16-26.		35
66	Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. , 1997, 32, 246-258.		69
67	The American Urological Association Symptom Score in the Evaluation of Men With Lower Urinary Tract Symptoms: at 2 years of followup, does it work?. <i>Journal of Urology</i> , 1996, 155, 1971-1974.	0.4	28
68	Differential Diagnosis of Prostatism: a 12-year Retrospective Analysis of Symptoms, Urodynamics and Satisfaction with Therapy. <i>Journal of Urology</i> , 1996, 155, 1305-1308.	0.4	48
69	The Ileal Ureter Neobladder is Associated with a High Success and a Low Complication Rate. <i>Journal of Urology</i> , 1996, 155, 1585-1588.	0.4	48
70	THE ROLE OF THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY FOR PROSTATE-SPECIFIC ANTIGEN IN THE SELECTION OF PATIENTS FOR RADICAL PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 1996, 23, 541-549.	1.8	19
71	Pediatric Continent Reservoirs and Colocystoplasty Created with Absorbable Staples. <i>Journal of Urology</i> , 1996, 156, 614-617.	0.4	9
72	Preoperative Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen Predicts Treatment Failure Following Radical Prostatectomy. <i>Journal of Urology</i> , 1996, 155, 1557-1562.	0.4	92

#	ARTICLE	IF	CITATIONS
73	Molecular staging of genitourinary malignancies. <i>Urology</i> , 1996, 47, 948-958.	1.0	23
74	Hypospadias repair by laser tissue soldering: Intraoperative results and follow-up in 30 children. <i>Urology</i> , 1996, 48, 616-623.	1.0	28
75	Pediatric Continent Reservoirs and Colocystoplasty Created with Absorbable Staples. <i>Journal of Urology</i> , 1996, 156, 614-617.	0.4	1
76	Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. <i>Cancer</i> , 1995, 75, 1642-1648.	4.1	105
77	Effect of demographic factors, urinary peak flow rates, and Boyarsky Symptom scores on patient treatment choice in benign prostatic hyperplasia. <i>Urology</i> , 1995, 45, 398-405.	1.0	39
78	Laser tissue soldering in urinary tract reconstruction: First human experience. <i>Urology</i> , 1995, 46, 261-266.	1.0	78
79	Urological Neurology and Urodynamics: Urodynamics and the Etiology of Post-Prostatectomy Urinary Incontinence: The Initial Columbia Experience. <i>Journal of Urology</i> , 1995, 153, 1034-1037.	0.4	72
80	Molecular Staging of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen. <i>Journal of Urology</i> , 1995, 153, 1373-1378.	0.4	73
81	Urology Peer Review at the National Institutes of Health. <i>Journal of Urology</i> , 1995, 154, 1866-1869.	0.4	4
82	Transition Zone Index as a Method of Assessing Benign Prostatic Hyperplasia: Correlation with Symptoms, Urine Flow and Detrusor Pressure. <i>Journal of Urology</i> , 1995, 154, 1764-1769.	0.4	170
83	The Incidence of Multifocal Renal Cell Carcinoma in Patients Who are Candidates for Partial Nephrectomy. <i>Journal of Urology</i> , 1995, 154, 968-971.	0.4	98
84	Absorbable Stapling Techniques in Bowel Reservoirs. <i>Atlas of the Urologic Clinics of North America</i> , 1995, 3, 69-80.	0.0	5
85	Molecular Staging of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen. <i>Journal of Urology</i> , 1995, , 1373-1378.	0.4	3
86	Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. <i>Cancer</i> , 1994, 74, 1667-1673.	4.1	44
87	Rapid construction of right colon pouch: Initial clinical experience. <i>Urology</i> , 1994, 43, 228-231.	1.0	13
88	Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. <i>Urology</i> , 1994, 43, 765-775.	1.0	287
89	Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. <i>Urology</i> , 1994, 43, 645-648.	1.0	28
90	Reconstruction of urinary and gastrointestinal tracts in total pelvic exenteration: Experience at columbia-presbyterian medical center. <i>Urology</i> , 1994, 44, 666-670.	1.0	11

#	ARTICLE	IF	CITATIONS
91	Neurotrophic Factors in the Rat Penis. Journal of Urology, 1994, 152, 2167-2172.	0.4	33
92	Urologists On a Tightrope: Coping with a Changing Economy. Journal of Urology, 1994, 151, 1-4.	0.4	62
93	Detection and Treatment of Prostate Cancer: Perspective of the Urologist. Journal of Urology, 1994, 152, 1695-1699.	0.4	28
94	PSA DENSITY (PSAD). Urologic Clinics of North America, 1993, 20, 653-663.	1.8	103
95	The Predictive Value of Flow Cytometry and Urinary Cytology in the Followup of Patients with Transitional Cell Carcinoma of the Bladder. Journal of Urology, 1992, 148, 293-296.	0.4	43
96	Renal Growth Factor Expression during the Early Phase of Experimental Hydronephrosis. Journal of Urology, 1992, 148, 510-514.	0.4	66
97	The Use of Prostate Specific Antigen Density to Enhance the Predictive Value of Intermediate Levels of Serum Prostate Specific Antigen. Journal of Urology, 1992, 147, 817-821.	0.4	573
98	Prostatic and Periprostatic Interstitial Temperature Measurements in Patients Treated with Transrectal Thermal Therapy (Local Intracavitary Microwave Hyperthermia). Journal of Urology, 1992, 147, 1562-1565.	0.4	22
99	Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. Journal of Urology, 1992, 147, 815-816.	0.4	669
100	Safety of urologic surgical intervention in the elderly. Geriatric Nephrology and Urology, 1992, 2, 105-108.	0.3	2
101	SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney International, 1991, 39, 1098-1103.	5.2	58
102	Ureteral Reconstruction and Bypass: Experience with Ileal Interposition, The Boari Flap-Psoas Hitch and Renal Autotransplantation. Journal of Urology, 1990, 143, 20-23.	0.4	112
103	Characterization of the Products of a Gene Expressed During Androgen-Programmed Cell Death and their Potential use as a Marker of Urogenital Injury. Journal of Urology, 1990, 143, 407-413.	0.4	79
104	Flow cytometric analysis of localized adenocarcinoma of the prostate: The use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. Prostate, 1990, 17, 155-164.	2.3	27
105	Chromosomal assignment of the human homologue encoding SGP-2. Biochemical and Biophysical Research Communications, 1990, 172, 160-164.	2.1	25
106	Gene expression in response to acute unilateral ureteral obstruction. Kidney International, 1989, 35, 1315-1319.	5.2	81
107	Urinary Diversion. Journal of Urology, 1989, 142, 1301-1301.	0.4	3
108	Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate, 1988, 13, 119-130.	2.3	117

#	ARTICLE	IF	CITATIONS
109	Contemporary cystectomy versus preoperative radiation plus cystectomy for bladder cancer. <i>Urology</i> , 1988, 32, 485-491.	1.0	6
110	Gene Expression in Renal Growth and Regrowth. <i>Journal of Urology</i> , 1988, 140, 1145-1148.	0.4	14
111	Stress Incontinence: Classification and Surgical Approach. <i>Journal of Urology</i> , 1988, 139, 727-731.	0.4	375
112	Complications of Artificial Urinary Sphincter Around Intestinal Segments in Reconstructed Exstrophy Patients. <i>Journal of Urology</i> , 1987, 138, 1123-1125.	0.4	23
113	Prognostic Variables in Patients with Transitional Cell Carcinoma of the Renal Pelvis and Proximal Ureter. <i>Journal of Urology</i> , 1987, 138, 1144-1145.	0.4	67
114	Enhanced expression of thec-myc protooncogene in high-grade human prostate cancers. <i>Prostate</i> , 1987, 11, 327-337.	2.3	180
115	Multiple primary neoplasms in association with prostate cancer in black and white patients. <i>Cancer</i> , 1987, 59, 380-384.	4.1	50
116	Combined Boari Bladder Flap-Psoas Bladder Hitch Procedure in Ureteral Replacement. <i>Scandinavian Journal of Urology and Nephrology</i> , 1986, 20, 279-284.	1.4	38
117	Flow cytometry: Role in monitoring transitional cell carcinoma of bladder. <i>Urology</i> , 1986, 28, 15-20.	1.0	41
118	Misonidazole as a Chemosensitizer in the Treatment of the Dunning Prostate Cancer Model. <i>Journal of Urology</i> , 1984, 131, 374-377.	0.4	2
119	Continent Urinary Diversion. <i>Journal of Urology</i> , 1984, 132, 1157-1158.	0.4	10
120	Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera. <i>Cancer</i> , 1983, 52, 1642-1646.	4.1	35
121	Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate. <i>Urology</i> , 1983, 21, 270-272.	1.0	16
122	Adjunctive therapy with interstitial irradiation for prostate cancer. <i>Urology</i> , 1982, 19, 395-398.	1.0	8
123	Health Risk and Management of Localized Prostate Cancer. <i>Cancer Treatment and Research</i> , 1982, , 121-142.	0.5	0
124	The Flow Rate Nomogram: II. Clinical Correlation. <i>Journal of Urology</i> , 1980, 123, 208-210.	0.4	177
125	Renal Autotransplantation for Recurrent Renal Colic. <i>Journal of Urology</i> , 1980, 123, 467-473.	0.4	33
126	Rapidly Expanding Retroperitoneal Mass. <i>Journal of Urology</i> , 1980, 123, 556-561.	0.4	3



#	ARTICLE	IF	CITATIONS
127	Benefits and complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Prostate, 1980, 1, 345-349.	2.3	9
128	Development of a carbon dioxide laser cystoscope. Lasers in Surgery and Medicine, 1980, 1, 183-190.	2.1	10
129	The Flow Rate Nomogram: I. Development. Journal of Urology, 1979, 122, 665-668.	0.4	283
130	The Controversy of Single Versus Multistaged Urethroplasty. Journal of Urology, 1978, 120, 414-417.	0.4	12
131	The Phentolamine Test in Neurogenic Bladder Dysfunction. Journal of Urology, 1977, 117, 481-485.	0.4	37
132	New look at pelvic exenteration. Urology, 1976, 7, 355-361.	1.0	9
133	Metastatic infection secondary to genitourinary tract sepsis. American Journal of Medicine, 1976, 61, 351-360.	1.5	50
134	Case 13-1976. New England Journal of Medicine, 1976, 294, 712-720.	27.0	212
135	Effects of Levodopa on the Bladder Outlet. Journal of Urology, 1975, 113, 803-805.	0.4	28
136	Thrombocytopenia with External Genital Gangrene. Journal of Urology, 1974, 112, 208-210.	0.4	8
137	Immunologic Reduction of Bladder Cancer Recurrence Rate. Journal of Urology, 1974, 111, 173-176.	0.4	88
138	Phenoxybenzamine in Neurogenic Bladder Dysfunction. II. Clinical Considerations. Journal of Urology, 1973, 110, 653-656.	0.4	139
139	Conservative Management of Renal Artery Embolus. Journal of Urology, 1973, 109, 138-143.	0.4	73
140	Phenoxybenzamine in Neurogenic Bladder Dysfunction. I. A Theory of Micturition. Journal of Urology, 1973, 110, 650-652.	0.4	135
141	PEDICLE PATCH URETHROPLASTY FOR CURE OF URETHRAL STRICTURE. Plastic and Reconstructive Surgery, 1973, 51, 1-7.	1.4	5
142	Oral Diuretics and Renal Painâ€”A Provocative Test. Journal of Urology, 1972, 108, 25-27.	0.4	2
143	Urethrocavernous Fistula: Complication of Cavernospongiosal Shunt. Journal of Urology, 1972, 108, 750-751.	0.4	23
144	Effect of Rabbit ALG on Cadaver Kidney Transplant Survival. Annals of Surgery, 1972, 176, 521-528.	4.2	15

#	ARTICLE	IF	CITATIONS
145	Pulmonary Cancer Metastatic to the Kidney—a Common Renal Neoplasm. <i>Journal of Urology</i> , 1971, 105, 492-496.	0.4	46
146	A Surgical Procedure Suggested for Certain Cases of Reduplicated Ureter. <i>Journal of Urology</i> , 1971, 105, 790-793.	0.4	6
147	Clinical Use of Rabbit Antihuman Lymphocyte Globulin in Cadaver-Kidney Transplantation. <i>New England Journal of Medicine</i> , 1971, 284, 1109-1115.	27.0	34
148	The Transverse Upper Abdominal “Chevron” Incision in Urological Surgery. <i>Journal of Urology</i> , 1968, 99, 528-532.	0.4	8